These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 2728081)

  • 21. Prognostic significance of 111indium-DTPA CSF flow studies in leptomeningeal metastases.
    Chamberlain MC; Kormanik PA
    Neurology; 1996 Jun; 46(6):1674-7. PubMed ID: 8649568
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Probenecid inhibition of methotrexate-cerebrospinal fluid pharmacokinetics in dogs.
    Ramu A; Fusner JE; Blaschke T; Glaubiger DL
    Cancer Treat Rep; 1978 Oct; 62(10):1465-70. PubMed ID: 581360
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Effects of infusion duration of high-dose methotrexate on cerebrospinal fluid drug levels in lymphoma patients].
    Lin XB; Zhou NN; Li S; Cai QQ; Xia ZJ; Liao H; Gao Y; Huang HQ
    Ai Zheng; 2008 Oct; 27(10):1100-5. PubMed ID: 18851792
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Methotrexate concentration in cerebrospinal fluid of the space created by tumor removal.
    Morikawa N; Mori T; Kawashima H; Takeyama M; Hori S
    Biol Pharm Bull; 2000 Jun; 23(6):774-7. PubMed ID: 10864035
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of cytosine arabinoside, methotrexate, nimustine and valproic acid in cerebrospinal fluid during cerebrospinal fluid perfusion chemotherapy.
    Morikawa N; Mori T; Abe T; Kawashima H; Takeyama M; Hori S
    Biol Pharm Bull; 2000 Jun; 23(6):784-7. PubMed ID: 10864038
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Direct administration of methotrexate into the central nervous system of primates. Part 1: Distribution and degradation of methotrexate in nervous and systemic tissue after intraventricular injection.
    Kimelberg HK; Kung D; Watson RE; Reiss FL; Biddlecome SM; Bourke RS
    J Neurosurg; 1978 Jun; 48(6):883-94. PubMed ID: 96228
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ventriculolumbar perfusion chemotherapy for the treatment of leptomeningeal carcinomatosis: a phase I study with pharmacokinetic data.
    Gwak HS; Lim HS; Shin SH; Yoo H; Han JY; Kim HT; Yun T; Lee JS; Lee SH
    Am J Clin Oncol; 2013 Oct; 36(5):491-9. PubMed ID: 22781384
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radioisotope CSF flow studies in leptomeningeal metastases.
    Chamberlain MC
    J Neurooncol; 1998; 38(2-3):135-40. PubMed ID: 9696363
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cerebrospinal fluid drug levels of leukemic children receiving intravenous 5 g/m2 methotrexate.
    Millot F; Rubie H; Mazingue F; Mechinaud F; Thyss A
    Leuk Lymphoma; 1994 Jun; 14(1-2):141-4. PubMed ID: 7920221
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A pharmacokinetic model for predicting the concentration of methotrexate in plasma subsequent to intrathecal injection.
    Ramu A; Fusner JE
    Isr J Med Sci; 1979 Jun; 15(6):494-9. PubMed ID: 582316
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical pharmacology of intrathecal methotrexate. I. Pharmacokinetics in nontoxic patients after lumbar injection.
    Bleyer WA; Dedrick RL
    Cancer Treat Rep; 1977 Jul; 61(4):703-8. PubMed ID: 577895
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of dose and repeat intravenous 24 hr infusions of methotrexate on cerebrospinal fluid availability in children with hematological malignancies.
    Thyss A; Milano G; Deville A; Manassero J; Renee N; Schneider M
    Eur J Cancer Clin Oncol; 1987 Jun; 23(6):843-7. PubMed ID: 3477462
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Methotrexate cerebrospinal fluid and serum concentrations after intermediate-dose methotrexate infusion.
    Evans WE; Hutson PR; Stewart CF; Cairnes DA; Bowman WP; Rivera G; Crom WR
    Clin Pharmacol Ther; 1983 Mar; 33(3):301-7. PubMed ID: 6600662
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections.
    Shapiro WR; Young DF; Mehta BM
    N Engl J Med; 1975 Jul; 293(4):161-6. PubMed ID: 806016
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Measurements of CSF biochemical tumor markers in patients with meningeal carcinomatosis and brain tumors.
    Nakagawa H; Kubo S; Murasawa A; Nakajima S; Nakajima Y; Izumoto S; Hayakawa T
    J Neurooncol; 1992 Feb; 12(2):111-20. PubMed ID: 1560255
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia.
    Csordas K; Hegyi M; Eipel OT; Muller J; Erdelyi DJ; Kovacs GT
    Anticancer Drugs; 2013 Feb; 24(2):189-97. PubMed ID: 23187460
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics following intraventricular administration of chemotherapy in patients with neoplastic meningitis.
    Fleischhack G; Jaehde U; Bode U
    Clin Pharmacokinet; 2005; 44(1):1-31. PubMed ID: 15634030
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative effects of citrovorum factor and carboxypeptidase G1 on cerebrospinal fluid-methotrexate pharmacokinetics.
    Abelson HT; Ensminger W; Rosowsky A; Uren J
    Cancer Treat Rep; 1978 Oct; 62(10):1549-52. PubMed ID: 309355
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intrathecal chemotherapy for patients with meningeal carcinomatosis.
    Yoshida S; Morii K
    Surg Neurol; 2005 Jan; 63(1):52-5; discussion 55. PubMed ID: 15639526
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Efficacy and Security of Intrathecal with Methotrexate in the Treatment of Meningeal Carcinomatosis].
    Wu X; Li J; Xiao J; Yang B; Yu L; Wu X; Wan J; Xu H; Kong J
    Zhongguo Fei Ai Za Zhi; 2016 May; 19(5):252-6. PubMed ID: 27215452
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.